N-alpha-phthaloylglutamine anhydride | 64552-24-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-alpha-phthaloylglutamine anhydride
• 英文别名: [5-amino-2-(1,3-dioxoisoindol-2-yl)-5-oxopentanoyl] 5-amino-2-(1,3-dioxoisoindol-2-yl)-5-oxopentanoate
• CAS: 64552-24-5
• 化学式: C₂₆H₂₂N₄O₉
• 分子量: 534.5
• InChiKey: MVXMSKLPHYGVLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  204
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Methods and compositions for inhibition of angiogenesis
  申请人：The Children's Medical Center Corporation

  公开号：EP1245229A2

  公开（公告）日：2002-10-02

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

  本发明包括一组能有效抑制血管生成的化合物。更具体地说，沙利度胺和各种相关化合物，如沙利度胺前体、类似物、代谢物和水解产物，已被证明可抑制血管生成。重要的是，这些化合物可以口服给药。
• Methods and compositions for treating cancer
  申请人：The Children's Medical Center Corporation

  公开号：EP1264597A2

  公开（公告）日：2002-12-11

  Thalidomide for treating solid and blood-borne tumours, wherein said tumour is a breast cancer, leukaemia, neoplastic disease of the bone marrow, Kaposi's sarcoma, hemangioma, rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, osteosarcoma, acoustic neuroma, neurofibroma, trachoma, or pyogenic granuloma; and for treating ocular neovascular disease, macular degeneration, proliferative vitreoretinopathy, retrolental fibroplasia, psoriasis, Crohn's disease, diabetic retinopathy, Osler-Weber-Rendu disease, hereditary hemorrhagic telangienctasia or osteoarthritis.

  沙利度胺用于治疗实体瘤和血源性肿瘤，其中所述肿瘤为乳腺癌、白血病、骨髓肿瘤性疾病、卡波西肉瘤、血管瘤、横纹肌肉瘤、尤文肉瘤、神经母细胞瘤、骨肉瘤、听神经瘤、神经纤维瘤、沙眼或化脓性肉芽肿； 用于治疗眼部新生血管疾病、黄斑变性、增殖性玻璃体视网膜病变、后牙龈纤维增生症、银屑病、克罗恩病、糖尿病视网膜病变、Osler-Weber-Rendu 病、遗传性出血性毛细血管扩张症或骨关节炎。
• Compositions for inhibition of anglogenesis
  申请人：The Children's Medical Center Corporation

  公开号：EP1586322A2

  公开（公告）日：2005-10-19

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

  本发明包括一组能有效抑制血管生成的化合物。更具体地说，沙利度胺和各种相关化合物，如沙利度胺前体、类似物、代谢物和水解产物，已被证明可抑制血管生成和治疗血管生成导致的疾病状态。此外，抗炎药物，如类固醇和非甾体抗炎药物，可单独或与沙利度胺及相关化合物联合使用，抑制血管生成相关疾病。重要的是，这些化合物可以口服给药。
• Compositions for inhibition of angiogenesis
  申请人：The Children's Medical Center Corporation

  公开号：EP2143444A9

  公开（公告）日：2013-02-27

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

  本发明包括一组能有效抑制血管生成的化合物。更具体地说，沙利度胺和各种相关化合物，如沙利度胺前体、类似物、代谢物和水解产物，已被证明可抑制血管生成和治疗血管生成导致的疾病状态。此外，抗炎药物，如类固醇和非甾体抗炎药物，可单独或与沙利度胺及相关化合物联合使用，抑制血管生成相关疾病。重要的是，这些化合物可以口服给药。
• Compositions for inhibition of anglogenesis comprising thalidomide and aspirin
  申请人：The Children's Medical Center Corporation

  公开号：EP2298300A1

  公开（公告）日：2011-03-23

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

  本发明包括一组能有效抑制血管生成的化合物。更具体地说，沙利度胺和各种相关化合物，如沙利度胺前体、类似物、代谢物和水解产物，已被证明可抑制血管生成和治疗血管生成导致的疾病状态。此外，抗炎药物，如类固醇和非甾体抗炎药物，可单独或与沙利度胺及相关化合物联合使用，抑制血管生成相关疾病。重要的是，这些化合物可以口服给药。